MUMBAI, INDIA, February 15, 2026 / EINPresswire.com / -- Lyze Labs (VEXHO), a premier provider of high-purity chemical standards and reference materials, today announced a strategic expansion of its logistics infrastructure. The expansion aims to support the global scientific community by ensuring reliable access to verified biotechnology compounds across the United States, Europe, and the Asia-Pacific regions. As the demand for precise analytical data in the biotechnology sector reaches new hei

Agreement adds new analyzer platforms and expands assay menu across key international markets SAN DIEGO, Feb. 16, 2026 /PRNewswire/ -- QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd., stock code: 688389), to expand QuidelOrtho's global immunoassay portfolio and accelerate customer access to scalable, high quality, cost-efficient solutions across select markets outside the United States. Lifotronic and Q Lifotron

Vidac Pharma to present recent clinical and strategic progress at the 19th European Life Sciences CEO Forum by Sachs Associates. Conferences such as Sachs provide an important platform to share developments in our clinical programs and strategic initiatives.” — Dr. Max Herzberg LONDON, UNITED KINGDOM, February 16, 2026 / EINPresswire.com / -- Vidac Pharma Holdings Plc. announces that Dr. Max Herzberg, Chairman and Chief Executive Officer of Vidac Pharma, will present at the 19th Annual European

Roche announced Monday that a Phase III study of Gazyva/Gazyvaro (obinutuzumab) in adults with primary membranous nephropathy met its primary endpoint, potentially setting up another approval for the anti-CD20 monoclonal antibody and the first for a therapy in this chronic autoimmune condition.The MAJESTY trial randomised 142 people with primary membranous nephropathy to receive Gazyva/Gazyvaro or tacrolimus. Results showed that significantly more people achieved complete remission at week 104 w

Eli Lilly's oral RET kinase inhibitor Retevmo (selpercatinib) significantly improved event-free survival (EFS) in patients with early-stage, RET fusion-positive non–small-cell lung cancer (NSCLC), the company announced Monday."We have consistently observed that cancer medicines can deliver their greatest impact when administered early in the course of a patient's treatment journey," said Jacob Van Naarden, president of Lilly Oncology. "The LIBRETTO-432 results support this observation, demonstra

CAIRO and QUEBEC CITY, Canada, Feb. 15, 2026 /PRNewswire/ - OPTEL, a global leader in track-and-trace solutions, and Techno Service, Egypt's premier industrial systems expert, today announced an exclusive partnership. The collaboration delivers a fully localized, end-to-end serialization and aggregation solution for pharmaceutical manufacturers and Third-Party Logistics (3PL) providers, combining OPTEL's proven global technology platform with Techno Service's deep local market expertise. Togethe

CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial in patients with advanced solid tumors. This marks a significant milestone in the global development of this innovative immunotherapy. The ongoing global multicenter Phase II trial is currently enrolling patients in Australia and China. The study design includes 15 cohorts evaluating both monotherapy and co

Belén Garijo, appointed first female CEO of Sanofi Sanofi appoints Belén Garijo as first female CEO, marking leadership change amid strategic challenges and investor concerns over future growth The French pharmaceutical giant Sanofi has appointed Belén Garijo, the current Chief Executive of Merck KGaA, as its new CEO from April. The appointment represents a historic moment for the company, as Garijo becomes the first woman to hold the top position. In a company statement, Sanofi confirmed the le

iStock, Deagreez The FDA in October 2025 granted bitopertin its Commissioner’s National Priority Voucher but after a shortened review time has decided the data did not support regulatory approval for treating erythropoietic protoporphyria. The FDA has declined to approve Disc Medicine’s bitopertin for a rare disease characterized by extreme, painful sunlight sensitivity, a rejection that comes just months after reports circulated that biologics head Vinay Prasad was skeptical of the drug. Dis

iStock, allanswart After the FDA’s decision to reject a review of Moderna’s mRNA-1010 flu shot, executives explain what Americans will miss out on as other nations embrace the technology. The rest of the world may get access to Moderna’s pair of influenza vaccines before the U.S. does after the FDA declined to even review the application for mRNA-1010, executives warned. This comes as the U.S. is facing a brutal flu season due to a mismatch in circulating strains as compared to the existing s